Pancreatic cancer vaccine shows promise in first human trial, preventing disease in high-risk patients
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Pancreatic cancer vaccine shows promise in first human trial, preventing disease in high-risk patients" is generating significant coverage in the Health category, with 4 articles from 4 distinct sources tracked by PULSE so far.
Outlets currently covering the story include CancerNetwork, Oncodaily, the-scientist.com and Fox News. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 2h ago.
Quick answers
Why is "Pancreatic cancer vaccine shows promise in first human trial, preventing disease" trending?
Because 4 independent news sources published 4 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (4)
- First-in-Human mKRAS Vaccine Elicits Durable T-Cell Responses in High-Risk PDAC CancerNetwork · 3h ago
- Anna Berkenblit: An Encouraging Early Data on a Mutant KRAS Vaccine to Prevent Pancreatic Cancer Oncodaily · 3h ago
- A Pancreatic Cancer Vaccine Shows Promise in a Phase 1 Clinical Trial the-scientist.com · 3h ago
- Pancreatic cancer vaccine shows promise in first human trial, preventing disease in high-risk patients Fox News · 3h ago
Topics
Related trends
A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses
An experimental KRAS-targeted vaccine has demonstrated a safe, durable immune response in individuals at high risk for pancreatic cancer.
Pancreatic cancer breakthrough has big implications for early detection effort - San Diego Union-Tribune
The European Medicines Agency has fast-tracked the review of an experimental pancreatic cancer pill amid reports of significant clinical trial outcomes.